Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Prostate Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 55 articles: HTML format

Single Articles

October 2021
1. KOPELKE S, Bartscht T, Schild SE, Tvilsted S, et al
   Frequency and Risk Factors of Sleep Disturbances in Patients With Prostate Cancer Assigned to Local or Loco-regional Radiotherapy.
   Anticancer Res. 2021;41:5165-5169.
   PubMed     Abstract available
   
   
   
2. TAKAI M, Kawakami K, Fujita Y, Kato T, et al
   Kartogenin Inhibits Prostate Cancer Cell Growth Through Smad2 Activation and Decreases Androgen Receptor Nuclear Localization.
   Anticancer Res. 2021;41:4753-4759.
   PubMed     Abstract available
   
   
   
3. FUJIMOTO N, Harada K, Shiota M, Tomisaki I, et al
   Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
   Anticancer Res. 2021;41:4687-4695.
   PubMed     Abstract available
   
   
   
4. KARLSSON S, Diaz Cruz MA, Faresjo M, Khamou AP, et al
   Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D3 in LNCaP Cells.
   Anticancer Res. 2021;41:4733-4740.
   PubMed     Abstract available
   
   
   September 2021
5. MASUDA H, Fujimoto A, Kanesaka M, Hou K, et al
   Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer.
   Anticancer Res. 2021;41:4443-4446.
   PubMed     Abstract available
   
   
   
6. MIYATA Y, Masato M, Mukae Y, Nakamura Y, et al
   Pathological Roles of Prostaglandin E2-specific E-type Prostanoid Receptors in Hormone-sensitive and Castration-resistant Prostate Cancer.
   Anticancer Res. 2021;41:4333-4341.
   PubMed     Abstract available
   
   
   
7. JACEWICZ M, Rud E, Galtung KF, Noor D, et al
   Cancer Detection Rates in Targeted Transperineal MRI-TRUS Elastic Fusion-guided Prostate Biopsies Performed Under Local Anesthesia.
   Anticancer Res. 2021;41:4395-4400.
   PubMed     Abstract available
   
   
   August 2021
8. JIMENEZ ROMERO ME, Gallego MC, Navarro Serrato JC, Sanchez Hurtado MA, et al
   Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors.
   Anticancer Res. 2021;41:3955-3968.
   PubMed     Abstract available
   
   
   
9. BLAS L, Shiota M, Yamada S, Ieiri K, et al
   Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer.
   Anticancer Res. 2021;41:3885-3889.
   PubMed     Abstract available
   
   
   
10. WATANABE H, Kawakami A, Sato R, Watanabe K, et al
    Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
    Anticancer Res. 2021;41:3753-3758.
    PubMed     Abstract available
    
    
    
11. OELRICH F, Junker H, Stope MB, Erb HHH, et al
    Gelsolin Governs the Neuroendocrine Transdifferentiation of Prostate Cancer Cells and Suppresses the Apoptotic Machinery.
    Anticancer Res. 2021;41:3717-3729.
    PubMed     Abstract available
    
    
    
12. STELLER D, Simon R, VON Bialy R, Hakim SG, et al
    Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
    Anticancer Res. 2021;41:3917-3923.
    PubMed     Abstract available
    
    
    July 2021
13. HARADA J, Miyata Y, Taima T, Matsuda T, et al
    Stage-specific Embryogenic Antigen-4 Expression in Castration-resistant Prostate Cancer and its Correlation With the Androgen Receptor.
    Anticancer Res. 2021;41:3327-3335.
    PubMed     Abstract available
    
    
    
14. ERB HHH, Oster MA, Gelbrich N, Cammann C, et al
    Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System.
    Anticancer Res. 2021;41:3271-3279.
    PubMed     Abstract available
    
    
    June 2021
15. PEPE P, Pepe L, Pennisi M, Fraggetta F, et al
    Prostate Cancer Diagnosis and Management During One Year of the COVID-19 Pandemic.
    Anticancer Res. 2021;41:3127-3130.
    PubMed     Abstract available
    
    
    
16. GARRIDO MM, Ribeiro RM, Kruger K, Pinheiro LC, et al
    Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?
    Anticancer Res. 2021;41:3067-3073.
    PubMed     Abstract available
    
    
    May 2021
17. ITO M, Sasamura K, Takase Y, Kotsuma T, et al
    Comparison of Physician-recorded Toxicities and Patient-reported Outcomes of Five Different Radiotherapy Methods for Prostate Cancer.
    Anticancer Res. 2021;41:2523-2531.
    PubMed     Abstract available
    
    
    
18. IINUMA K, Kawakami K, Mizutani K, Fujita Y, et al
    miRNA-93 in Serum Extracellular Vesicles Before and After Low Dose Rate Prostate Brachytherapy.
    Anticancer Res. 2021;41:2411-2418.
    PubMed     Abstract available
    
    
    April 2021
19. SEKITO S, Terabe T, Shibahara T, Onishi T, et al
    Usefulness of Biparametric Magnetic Resonance Imaging Combined With Prostate Specific Antigen Density in Pre-biopsy Detection of Clinically Insignificant Prostate Cancer.
    Anticancer Res. 2021;41:2183-2186.
    PubMed     Abstract available
    
    
    
20. FERINI G, Tripoli A, Molino L, Cacciola A, et al
    How Much Daily Image-guided Volumetric Modulated Arc Therapy Is Useful for Proctitis Prevention With Respect to Static Intensity Modulated Radiotherapy Supported by Topical Medications Among Localized Prostate Cancer Patients?
    Anticancer Res. 2021;41:2101-2110.
    PubMed     Abstract available
    
    
    
21. HAN Q, Hoffman RM
    Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.
    Anticancer Res. 2021;41:1921-1926.
    PubMed     Abstract available
    
    
    March 2021
22. CHOI JH, Choi SM, Lee SW, Jeh SU, et al
    Expression Patterns of ERalpha, ERbeta, AR, SIRT1, SIRT2, and SIRT3 in Prostate Cancer Tissue and Normal Prostate Tissue.
    Anticancer Res. 2021;41:1377-1386.
    PubMed     Abstract available
    
    
    
23. WALTERS C, Reed M, Bartholomew S, Bommareddy A, et al
    Autophagy Induction by alpha-Santalol in Human Prostate Cancer Cells.
    Anticancer Res. 2021;41:1197-1202.
    PubMed     Abstract available
    
    
    
24. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available
    
    
    February 2021
25. GREWAL K, Grewal K, Tabbara IA
    PARP Inhibitors in Prostate Cancer.
    Anticancer Res. 2021;41:551-556.
    PubMed     Abstract available
    
    
    January 2021
26. KODITZ B, Stog A, GObel H, Heidegger I, et al
    Vimentin 3 Expression in Prostate Cancer Cells.
    Anticancer Res. 2021;41:169-174.
    PubMed     Abstract available
    
    
    
27. KANO H, Kadono Y, Kadomoto S, Iwamoto H, et al
    Similar Recurrence Rate Between Gleason Score of Six at Positive Margin and Negative Margin After Radical Prostatectomy.
    Anticancer Res. 2021;41:509-516.
    PubMed     Abstract available
    
    
    December 2020
28. HORI A, Sahashi H, Sano S, Matsumiya E, et al
    Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:7101-7108.
    PubMed     Abstract available
    
    
    
29. KELLOKUMPU-LEHTINEN PL, Marttila T, Jekunen A, Hervonen P, et al
    Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
    Anticancer Res. 2020;40:6915-6921.
    PubMed     Abstract available
    
    
    
30. NAM RK, Benatar T, Amemiya Y, Sherman C, et al
    Mir-139 Regulates Autophagy in Prostate Cancer Cells Through Beclin-1 and mTOR Signaling Proteins.
    Anticancer Res. 2020;40:6649-6663.
    PubMed     Abstract available
    
    
    November 2020
31. OGASAWARA N, Nakiri M, Kurose H, Ueda K, et al
    Longitudinal Changes in Health-related Quality of Life After (125)I Low-dose-rate Brachytherapy for Localized Prostate Cancer.
    Anticancer Res. 2020;40:6443-6456.
    PubMed     Abstract available
    
    
    
32. SIVONOVA MK, Jurecekova J, Kaplan P, Hives M, et al
    Association of MDM2 T309G (rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population.
    Anticancer Res. 2020;40:6257-6264.
    PubMed     Abstract available
    
    
    
33. BAI L, Li X, Ma X, Zhao R, et al
    In Vitro Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells.
    Anticancer Res. 2020;40:6051-6062.
    PubMed     Abstract available
    
    
    
34. BUWENGE M, Alitto AR, Cilla S, Capocaccia I, et al
    Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial.
    Anticancer Res. 2020;40:6499-6503.
    PubMed     Abstract available
    
    
    October 2020
35. YUNO T, Miyata Y, Matsuo T, Mukae Y, et al
    Relationship Between Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer.
    Anticancer Res. 2020;40:5567-5575.
    PubMed     Abstract available
    
    
    
36. KODITZ B, Fries JWU, GObel H, Paffenholz P, et al
    Mxi-2 Dependent Regulation of p53 in Prostate Cancer.
    Anticancer Res. 2020;40:5539-5544.
    PubMed     Abstract available
    
    
    
37. MIYASHITA M, Tomogane M, Nakamura Y, Shimizu T, et al
    Sphere-derived Prostate Cancer Stem Cells Are Resistant to gammadelta T Cell Cytotoxicity.
    Anticancer Res. 2020;40:5481-5487.
    PubMed     Abstract available
    
    
    September 2020
38. MINAMI H, Ando Y, Tamura K, Tajima T, et al
    Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:5229-5235.
    PubMed     Abstract available
    
    
    
39. ISHII A, Shigemura K, Kitagawa K, Sung SY, et al
    Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:5107-5114.
    PubMed     Abstract available
    
    
    
40. MIYAO T, Koike H, Sekine Y, Ohtsu A, et al
    YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression.
    Anticancer Res. 2020;40:5091-5095.
    PubMed     Abstract available
    
    
    August 2020
41. BUWENGE M, Deodato F, Dominsky N, Ntreta M, et al
    Radiotherapy of Prostate Carcinoma: A Comparison of the Predictive Role of EAU Versus NCCN Risk Stratification Systems.
    Anticancer Res. 2020;40:4413-4418.
    PubMed     Abstract available
    
    
    
42. SHIMURA Y, Suga Y, Itai S, Iwamoto H, et al
    Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:4291-4297.
    PubMed     Abstract available
    
    
    July 2020
43. LIAO PC, Hung SC, Hu JC, Chiu KY, et al
    Retzius-sparing Robotic-assisted Radical Prostatectomy Facilitates Early Continence Regardless of Neurovascular Bundle Sparing.
    Anticancer Res. 2020;40:4075-4080.
    PubMed     Abstract available
    
    
    June 2020
44. SUZUKI K, Terakawa T, Jimbo N, Inaba R, et al
    Clinical Features of Treatment-related Neuroendocrine Prostate Cancer: A Case Series.
    Anticancer Res. 2020;40:3519-3526.
    PubMed     Abstract available
    
    
    
45. KODIYAN J, Ashamalla M, Guirguis A, Ashamalla H, et al
    Race Does Not Affect Survival in Patients With Prostate Cancer Treated With Radiation Therapy.
    Anticancer Res. 2020;40:3307-3314.
    PubMed     Abstract available
    
    
    May 2020
46. OU YC, Chang KH, Tung MC, Tsai IJ, et al
    Building a Nomogram for Prediction of Prostate Cancer in Patients With Preoperatively Suspected Prostate Cancer.
    Anticancer Res. 2020;40:2995-3002.
    PubMed     Abstract available
    
    
    
47. HAN Q, Tan Y, Hoffman RM
    Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
    Anticancer Res. 2020;40:2813-2819.
    PubMed     Abstract available
    
    
    
48. WANG S, Tailor K, Kwabi-Addo B
    Androgen-induced Epigenetic Profiles of Polycomb and Trithorax Genes in Prostate Cancer Cells.
    Anticancer Res. 2020;40:2559-2565.
    PubMed     Abstract available
    
    
    
49. ZHANG B, Leech M
    A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
    Anticancer Res. 2020;40:2419-2428.
    PubMed     Abstract available
    
    
    April 2020
50. OVCARICEK PP, Frobe A, Verburg FA, Murgic J, et al
    Association of Triiodothyronine Levels With Prostate Cancer Histopathological Differentiation and Tumor Stage.
    Anticancer Res. 2020;40:2323-2329.
    PubMed     Abstract available
    
    
    
51. NAKANO T, Kadono Y, Iwamoto H, Yaegashi H, et al
    Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:2291-2296.
    PubMed     Abstract available
    
    
    
52. NAKAMURA R, Hirata T, Suzuki O, Otani K, et al
    Stereotactic Body Radiotherapy Using CyberKnife(R) for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial.
    Anticancer Res. 2020;40:2053-2057.
    PubMed     Abstract available
    
    
    
53. MASIUK M, Lewandowska M, Dobak E, Urasinska E, et al
    Nucleolin and Nucleophosmin Expression in Gleason 3 and Gleason 4 Prostate Cancer With Seminal Vesicles Invasion (pT3b).
    Anticancer Res. 2020;40:1973-1979.
    PubMed     Abstract available
    
    
    March 2020
54. PLOSKONOS MV, Syatkin SP, Neborak EV, Hilal A, et al
    Polyamine Analogues of Propanediamine Series Inhibit Prostate Tumor Cell Growth and Activate the Polyamine Catabolic Pathway.
    Anticancer Res. 2020;40:1437-1441.
    PubMed     Abstract available
    
    
    
55. UCHIDA H, Hirata T, Otani K, Suzuki O, et al
    Assessment of Daily Replanning and Geometrical Variation of High-dose-rate Brachytherapy for the Prostate.
    Anticancer Res. 2020;40:1677-1682.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: